Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05868525 · ClinicalTrials.gov registry record · Phase 4
Stroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA).
A Phase 4 study of Blunt Cerebrovascular Injury, sponsored by Loma Linda University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 98
- Enrollment target
- 1
- Study location
NCT05868525 is a Phase 4 study of Blunt Cerebrovascular Injury that is actively recruiting participants, run by Loma Linda University. The registered enrollment target is 98 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05868525, a Phase 4 study of Blunt Cerebrovascular Injury, is actively recruiting participants, sponsored by Loma Linda University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 98 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to compare difference between Aspirin 81 mg and Aspirin 325 mg in preventing strokes in patients with head and neck vessels injury. The main questions it aims to answer are: * If Aspirin 81 mg efficacy in prevention of stroke in patients with head and neck vessels injury is not lower than and Aspirin 325 mg. * If rate of hemorrhagic complications in patients with head and neck vessels injury taking Aspirin 81 mg is not higher than patients that take Aspirin 325 mg.
Conditions Studied
Interventions
- DRUG Aspirin 325Mg Tab, Aspirin 81Mg Tab
Study Locations (1)
California
- Loma Linda University Medical Center - Loma Linda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2023-08-23 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05868525
The ClinicalTrials.gov registry entry for NCT05868525 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loma Linda University, which has 237 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Blunt Cerebrovascular Injury appearing as the primary indexed condition, and to 1 intervention - of which Aspirin 325Mg Tab, Aspirin 81Mg Tab is the first listed.
NCT05868525 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05868525 about?
NCT05868525 is a clinical study titled "Stroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA).". The goal of this clinical trial is to compare difference between Aspirin 81 mg and Aspirin 325 mg in preventing strokes in patients with head and neck vessels injury. The main questions it aims to answer are: * If Aspirin 81 mg efficacy in prevention of stroke in patients with head and neck vessel...
What is the current status of trial NCT05868525?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 98 participants. The study started on 2023-08-23. Estimated completion is 2026-12.
What conditions does trial NCT05868525 study?
This clinical trial studies the following conditions: Blunt Cerebrovascular Injury.
What interventions are being tested in trial NCT05868525?
The interventions under investigation include: Aspirin 325Mg Tab, Aspirin 81Mg Tab (DRUG).
Who is sponsoring clinical trial NCT05868525?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05868525 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.